News Agency
Men's Weekly

Keymed Biosciences Announces 2023 Annual Results and Business Updates

  • Written by PR Newswire
  • Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by the China's NMPA and granted priority review.
  • Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of the clinical trial are positive with co-primary endpoints...

Read more: Keymed Biosciences Announces 2023 Annual Results and Business Updates

Steps to Take When Facing a Commercial Lease Dispute in Australia

A commercial lease dispute can disrupt business operations, especially when the business premises are central to generating revenue. This article outlines practical steps to take when a disagreement arises under a commercial lease in Australia and how, as a tenant, you can... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion